ClinicalTrials.gg
CompletedNCT03757338Updated Nov 29, 2018

Bioequivalence Study of a Test Capsule Formulation of Fingolimod With the Reference Capsule Formulation of Fingolimod

A Phase 1 interventional study of Fingolimod Reference Formulation and Fingolimod Test Formulation in Healthy Volunteers, sponsored by Asofarma S.A.I. y C.. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-29.

Sponsored by Asofarma S.A.I. y C. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 1 month after the study started (first participant enrolled Oct 2015, registered Nov 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The study evaluates the bioequivalence of the Test formulation, 0.5 mg Fingolimod HCl capsule (Asofarma S.A.I. y C. on behalf of Tolmar, Batch No. 22264), relative to that of the Reference formulation, 0.5 mg Gilenya® (fingolimod) capsule (Novartis Pharmaceuticals, Batch No. S0099), following oral administration of a single oral dose of 3 x 0.5 mg in healthy, adult, male and female subjects under fasting conditions.

Read the detailed description

This was a single centre, single dose, blinded, two treatment, two period, two sequence, two-way crossover, randomized study conducted under medical supervision at Zenith Technology Corporation Limited's Clinical Site and involving 32 healthy adult subjects.

All subjects received either the Test or the Reference product under fasting conditions in each of the two treatment periods. In Period 1, one half of the subjects (16) were scheduled to receive 3 x 0.5 mg Fingolimod HCl capsules (Test); and one half of the subjects (16) were scheduled to receive 3 x 0.5 mg Gilenya® capsules (Reference). Each subject was scheduled to receive the alternate treatment in Period 2.

The two treatments were administered with 240 ml of ambient-temperature water after an overnight fast of at least 10 hours. Subjects did not receive any food until at least 4 hours post-dose. The capsules were swallowed whole.

During each study period, subjects were confined to the Zenith Clinical Site from at least 12 hours prior to drug administration, until after the 24-hour post-dose blood draw. Blood samples (18 x 10 ml) were collected at specified intervals during the in-house period from pre-dose (0 hours) out to 24 hours post-dose. Subjects returned to Zenith premises for the collection of additional blood samples (4 x 10 ml) at 32, 48, 56 and 72 hours post-dose. A total of 22 x 10 ml blood samples were collected in each study period.

The doses in the two treatment periods were separated by a washout period of at least 42 days and the project duration was 46 days for subject dosing and blood sampling over two periods.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

This is the only study on the registry with Asofarma S.A.I. y C. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written for the participation in the study.
  • Aged between 18 and 45 years, inclusive.
  • All females of must have a negative serum pregnancy test 3 days prior to dosing in both study periods.
  • Females of childbearing potential must agree to acceptable method of (as agreed with the study doctor) or abstain from sexual activity during the study.
  • (BMI) within 18 - 30 kg/m2, inclusive, with body mass above 45 kg.
  • Normal, healthy individuals as determined by medical history, physical examination, vital signs, and laboratory tests.
  • Non-smoker (for at least 6 months). This includes all tobacco products and nicotine containing patches and gums.
  • Must abstain from consuming alcohol and caffeine and remain chocolate free for 48 hours prior to the study and throughout each study period (i.e. until 72 hours post-dosing in each period).
  • Non-consumption of grapefruits or oranges, grapefruit and/or orange juice and any grapefruit and/or orange products for 1 week prior to the study and throughout the study (i.e. until 72 hours after receiving the final dose).
  • Subjects must agree and be able to follow the study procedures, in the Investigator's opinion.

Exclusion criteria

Exclusion Criteria:

  • Known to fingolimod, its analogues or of the tested drug or the reference drug, lactose malabsorption, glucose-galactose malabsorption or Lapp lactase deficiency.
  • Aggravated history of allergies (evidence of anaphylactic shock or Quincke's edema).
  • History of gastrointestinal (GI), hepatic or renal abnormality or any other abnormality, which, in the Investigator's opinion, may affect absorption, distribution, metabolism and excretion of the IMPs (e.g. operative interventions to the GI tract other than appendectomy).
  • Pregnant or breastfeeding females.
  • Acute infectious diseases within 4 weeks before the study start.
  • Significant cardio-vascular, pulmonary, hematologic, neurologic, psychiatric, endocrine, immunologic, ophthalmologic or dermatologic disease.
  • Subjects who have had any severe eye problems or conditions especially inflammation of the eye, such as uveitis.
  • Vital signs measured in the seated position: heart rate \<50 or >90 beats per minute or systolic BP \<90 mmHg or >160 mmHg or diastolic BP \<50 mmHg or >90 mmHg.
  • Subjects with prolonged (defined as >450 msec for males and >470 msec for females).
  • Any laboratory abnormalities at screening, including potassium, , asparte transaminase () and alanine transaminase (ALT) blood levels.
  • Evidence of routine consumption of more than 10 units of alcohol per week within 6 months before screening (1 unit of alcohol is equivalent to 500 ml of beer, 200 ml of wine or 50 ml of spirit), positive breath test for alcohol or alcohol consumption within 48 hours prior to the study start.
  • Evidence of any drug abuse within one year prior to the study start or positive urine drug and prohibited medication screen.
  • Concomitant drug therapy of any kind with the exception of prescribed hormonal .
  • Having received vaccinations within 1 month prior to dosing or any planned vaccination within 2 months of the last dose of fingolimod.
  • Administration of any medication that can cause a significant effect onto hemodynamics or liver function within 30 days prior to the study start.
  • Administration of any medications which can induce or inhibit the drug hepatic metabolism via CYP1A2, CYP2D6, CYP2C8, and CYP17 (hepatic metabolism inducers include barbiturates, carbamazepine, phenytoin, glucocorticosteroids, omeprazole; hepatic metabolism inhibitors include antidepressants, cimetidine, diltiazem, macrolides, imidazole, neuroleptics, verapamil, fluoroquinolones, antihistamine drugs), as well as herbal preparations and extracts within 30 days prior to the study start.
  • Administration of any injectable deposit (sustained release) formulations or drug implants within 3 months prior to the study drug administration.
  • Participation in any clinical study within 60 days prior to the study start.
  • Donation or loss of more than 450 ml of blood within 2 months prior to the screening visit.
  • Possible difficulties with study drug swallowing.
  • History of tuberculosis or participation in the tuberculosis control program.
  • Herpes simplex or varicella zoster virus infection including cold sore, genital herpes, chickenpox or shingles.
  • (HIV) positive test, positive test for or C.
  • Other acute or chronic medical or mental conditions, laboratory abnormalities which may increase risk associated with the study participation or with study drug administration or which may affect interpretation of the study results and, in the Investigator's opinion, make the subject non-eligible for participation in this study.
  • Inability of the subject to follow the requirements of the study.
  • Employees of the study Sponsor.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Active comparator
    Fingolimod Reference Formulation

    0.5 mg Fingolimod capsule (manufactured by Novartis, Batch No. S0099), orally administered as a single dose of 3 x 0.5 mg capsules.

    Drug: Fingolimod Reference Formulation

  • Experimental
    Fingolimod Test Formulation

    0.5 mg Fingolimod capsule (manufactured by manufactured by Asofarma S.A.I. y C. on behalf of Tolmar, Batch No. 22264), orally administered as a single dose of 3 x 0.5 mg capsules.

    Drug: Fingolimod Test Formulation

Interventions

  • DrugFingolimod Reference Formulation

    To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the reference product produced by Novartis Pharmaceutical with the proposed test product manufactured by Asofarma S.A.I. y C. in healthy volunteers, under fasted conditions.

    Also known as: Gylenia®

  • DrugFingolimod Test Formulation

    To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the proposed test product manufactured by Asofarma S.A.I. y C. with the reference product produced by Novartis Pharmaceutical in healthy volunteers, under fasted conditions.

    Also known as: Lebrina®

06

What researchers measure

Primary outcomes

  1. Fingolimod plasma Cmax (maximum plasma concentration) when administered as a single oral dose of 3 x 0.5 mg capsule of the test versus reference product.

    Fingolimod plasma Cmax will be calculated based on plasma Fingolimod concentrations within 1 hour pre-dose (time 0) and at 1, 2, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24, 32, 48, 56 and 72 hours post-dose.

    Time frame: Measurement within 72 hours post-dose.

  2. Fingolimod AUC0-t (area under the plasma concentration-time curve from time of intake until the last quantifiable concentration) when administered as a single oral dose of 3 x 0.5 mg capsule of the test versus reference product.

    Fingolimod AUC0-t will be calculated based on plasma Fingolimod concentrations within 1 hour pre-dose (time 0) and at 1, 2, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24, 32, 48, 56 and 72 hours post-dose.

    Time frame: Measurement within 72 hours post-dose.

  3. Fingolimod AUC0-∞ (area under the plasma concentration-time curve from time of intake until infinity) when administered as a single oral dose of 3 x 0.5 mg capsule of the test versus reference product.

    Fingolimod AUC0-∞ will be calculated based on plasma Fingolimod concentrations within 1 hour pre-dose (time 0) and at 1, 2, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24, 32, 48, 56 and 72 hours post-dose.

    Time frame: Measurement within 72 hours post-dose.

Secondary outcomes

  1. Fingolimod elimination t1/2 (elimination half-life), when administered as a single oral dose of 3 x 0.5 mg capsule of the test versus reference product.

    Fingolimod t1/2 will be calculated based on plasma Fingolimod concentrations within 1 hour pre-dose (time 0) and at 1, 2, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24, 32, 48, 56 and 72 hours post-dose.

    Time frame: Measurement within 72 hours post-dose.

  2. Fingolimod Tmax (time to Cmax), when administered as a single oral dose of 3 x 0.5 mg capsule of the test versus reference product.

    Fingolimod Tmax will be calculated based on plasma Fingolimod concentrations within 1 hour pre-dose (time 0) and at 1, 2, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24, 32, 48, 56 and 72 hours post-dose.

    Time frame: Measurement within 72 hours post-dose.

Other outcomes

  1. Fingolimod Phosphate plasma Cmax (maximum plasma concentration) when administered as a single oral dose of 3 x 0.5 mg capsule of the test versus reference product.

    Fingolimod Phosphate plasma Cmax will be calculated based on plasma Fingolimod concentrations within 1 hour pre-dose (time 0) and at 1, 2, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24, 32, 48, 56 and 72 hours post-dose.

    Time frame: Measurement within 72 hours post-dose.

  2. Fingolimod Phosphate AUC0-t (area under the plasma concentration-time curve from time of intake until the last quantifiable concentration ) when administered as a single oral dose of 3 x 0.5 mg capsule of the test versus reference product.

    Fingolimod Phosphate AUC0-t will be calculated based on plasma Fingolimod concentrations within 1 hour pre-dose (time 0) and at 1, 2, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24, 32, 48, 56 and 72 hours post-dose.

    Time frame: Measurement within 72 hours post-dose.

  3. Fingolimod Phosphate AUC0-∞ (area under the plasma concentration-time curve from time of intake until infinity ) when administered as a single oral dose of 3 x 0.5 mg capsule of the test versus reference product.

    Fingolimod Phosphate AUC0-∞ will be calculated based on plasma Fingolimod concentrations within 1 hour pre-dose (time 0) and at 1, 2, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24, 32, 48, 56 and 72 hours post-dose.

    Time frame: Measurement within 72 hours post-dose.

  4. Fingolimod Phosphate elimination t1/2 (elimination half-life) when administered as a single oral dose of 3 x 0.5 mg capsule of the test versus reference product.

    Fingolimod Phosphate elimination t1/2 will be calculated based on plasma Fingolimod concentrations within 1 hour pre-dose (time 0) and at 1, 2, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24, 32, 48, 56 and 72 hours post-dose.

    Time frame: Measurement within 72 hours post-dose.

  5. Fingolimod Phosphate Tmax (time to Cmax) when administered as a single oral dose of 3 x 0.5 mg capsule of the test versus reference product.

    Fingolimod Phosphate Tmax will be calculated based on plasma Fingolimod concentrations within 1 hour pre-dose (time 0) and at 1, 2, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 24, 32, 48, 56 and 72 hours post-dose.

    Time frame: Measurement within 72 hours post-dose.

07

Study locations

1 site
  • Zenith Clinical Site
    Dunedin, 9010, New Zealand
08

References and documents

Publications

  • Food and Drug Administration, USA. Bioequivalence Recommendations for fingolimod, Aug 2011.
  • Australian Product Information, Gilenya, 1 April 2015
  • Hung NA, Costa FG, Hung CT, Rosenberg ME. Bioequivalence Study of 2 Capsule Formulations of Fingolimod 0.5 mg Assessing Both Parent Drug and Active Metabolite in New Zealand Healthy Subjects (Truncated Design). Clin Pharmacol Drug Dev. 2020 Jul;9(5):610-620. doi: 10.1002/cpdd.813. Epub 2020 May 28. PubMed 32468719 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Jan 2016, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2018
First posted
Nov 28, 2018
StartActual
Oct 23, 2015
Primary completionActual
Jan 26, 2016
CompletionActual
Jan 26, 2016
Last update
Nov 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03757338
Lead sponsor
Asofarma S.A.I. y C.
Collaborators
Zenith Technology Corporation Limited
Responsible party
Sponsor
First posted
Nov 28, 2018
Start date
Oct 23, 2015
Primary completion
Jan 26, 2016
Completion
Jan 26, 2016
Last update
Nov 29, 2018

Study contacts

Noelyn A Hung, MB ChB
principal investigator · Zenith Technology Corporation Ltd, 156 Frederick Street, Dunedin, New Zealand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion